Nichols & Pratt Advisers LLP MA Grows Holdings in IQVIA Holdings Inc. $IQV

Nichols & Pratt Advisers LLP MA raised its stake in IQVIA Holdings Inc. (NYSE:IQV) by 8.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 122,603 shares of the medical research company’s stock after buying an additional 9,684 shares during the period. IQVIA comprises about 1.5% of Nichols & Pratt Advisers LLP MA’s investment portfolio, making the stock its 23rd biggest position. Nichols & Pratt Advisers LLP MA owned 0.07% of IQVIA worth $23,287,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC boosted its position in IQVIA by 244.4% during the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after buying an additional 2,537 shares during the period. Empowered Funds LLC raised its stake in IQVIA by 102.1% in the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after buying an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC purchased a new position in IQVIA during the 2nd quarter valued at about $514,000. Farther Finance Advisors LLC raised its stake in IQVIA by 34.0% during the second quarter. Farther Finance Advisors LLC now owns 398 shares of the medical research company’s stock valued at $63,000 after buying an additional 101 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in IQVIA by 5.8% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 27,185 shares of the medical research company’s stock worth $4,284,000 after acquiring an additional 1,489 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of IQVIA stock opened at $231.50 on Tuesday. The company has a market capitalization of $39.42 billion, a PE ratio of 31.76, a price-to-earnings-growth ratio of 2.34 and a beta of 1.36. The stock’s fifty day moving average is $231.00 and its two-hundred day moving average is $209.37. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $247.04. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Barclays set a $230.00 price objective on IQVIA in a report on Monday, December 15th. BMO Capital Markets started coverage on shares of IQVIA in a research report on Thursday, November 13th. They issued an “outperform” rating and a $260.00 price target on the stock. Robert W. Baird set a $258.00 price target on shares of IQVIA and gave the company an “outperform” rating in a report on Wednesday, October 29th. UBS Group boosted their price objective on IQVIA from $250.00 to $280.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Finally, Hsbc Global Res raised IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $251.06.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.